Library
Íslendingur
Also commonly known as IAP. A selective serotonin releasing agent with psychedelic and empathogenic properties. Users have often reported issues with the drug causing overheating and unwelcome bowel movements.
Also known as: Indanylaminopropane, indanylamphetamine, 5-apdi, 5-iap, Indanylaminopropane, Indanylamphetamine, 5-IAP, 5-APDI
Classification
- Chemical: Amphetamine
- Psychoactive: Entactogen
- Psychoactive: Psychedelic
- Psychoactive: Stimulant
- Tag: Empathogen
- Tag: Research-Chemical
- Tag: Tentative
Effects
- Increased Energyalertness
- Decreased Need For Sleep
- Decreased Appetite
- Weight Loss
- Sweating
- Distrubed Sleep Patterns
- Euphoria
- Increased Sociability
- Mood Lift
- Excessive Talking
- Agressiveness
- Moodiness
- Increased Sexuality
- Visual And Audiotory Hallucinations Itchiness
- Increased Music Appreciation
- Closed Eye Visuals
- Open Eye Visuals
- Tracers
Routes of Administration
Oral
Dosage
- Common: 25-50 mg
- Light: 15-25 mg
- Strong: 50-75 mg
- Heavy: 75+ mg
- Threshold: 10 mg
Duration
- Onset: 0.5-1.5 h
- Peak: 2-5 h
- Offset: 3-6 h
- After Effects: 1-6 h
- Total Duration: 8-14 h
Insufflated
Dosage
- Heavy: 30+ mg
- Light: 5-10 mg
- Common: 10-20 mg
- Strong: 20-30 mg
- Threshold: 5 mg
Duration
- Onset: 0.08-0.25 h
- Peak: 1-3 h
- Offset: 2-5 h
- After Effects: 1-6 h
- Total Duration: 6-12 h
Intravenous
Dosage
- Heavy: 15+ mg
- Light: 3-5 mg
- Common: 5-10 mg
- Strong: 10-15 mg
- Threshold: 2 mg
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.